A Study of Memantine Hydrochloride (Namenda) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders

Trial Profile

A Study of Memantine Hydrochloride (Namenda) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2016

At a glance

  • Drugs Memantine (Primary)
  • Indications Asperger syndrome; Autistic disorder; Pervasive child development disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 07 May 2013 Planned end date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 14 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top